The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

Loosely regulated online platforms are promoting powerful obesity shots as a universal weight-loss solution. Photographer: ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Research has revealed that GLP-1 agonist medications work, in part, by suppressing appetite signaling in the brain. Many ...

A new once-daily weight loss pill developed by Novo Nordisk has shown strong results in helping people with obesity lose ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...

Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's ...

A new approval allows the weight-loss drug Mounjaro to be used for moderate to severe obstructive sleep apnea in adults with obesity. The decision follows growing evidence that tirzepatide’s strong ...